Dr. Bonwetsch is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
79 Sand Pit Rd
suite 301
Danbury, CT 06810Phone+1 203-748-2551Fax+1 203-739-8970
Summary
- Robert Bonwetsch, MD is a Neurologist based out of Danbury, CT, who also specializes in Epilepsy and Neurophysiology. His education and training include a Chief Residency in Neurology, a Residency in Neurology, and a Clinical Neurophysiology fellowship. He graduated from the University of Hamburg. He has experience in electromyography, epilepsy, movement disorders, seizures, and traumatic brain injury-related psychosis. Dr. Bonwetsch has published numerous studies in peer-reviewed journals, with some being heavily cited. He has participated in clinical trials related to Parkinson's Disease and has earned the CMS Meaningful Use Stage 1 Certification from Allscripts Enterprise EHR, Allscripts in 2012-2013.
Education & Training
National Institutes of Health Clinical CenterFellowship, Clinical Neurophysiology, 2003 - 2005
Drexel University College of Medicine/Hahnemann University HospitalChief Residency, Neurology, 2003 - 2003- Drexel University College of Medicine/Hahnemann University HospitalResidency, Neurology, 2000 - 2003
University Hamburg, Krankenhaus Eppendorf, Fak MedClass of 1998
Certifications & Licensure
CT State Medical License 2004 - 2025
NY State Medical License 2016 - 2025
PA State Medical License 2000 - 2004- American Board of Psychiatry and Neurology Neurology
- American Board of Psychiatry and Neurology Clinical Neurophysiology
- American Board of Psychiatry and Neurology Epilepsy
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012-2013
Clinical Trials
- A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease Start of enrollment: 2020 Dec 30
- An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's Disease Start of enrollment: 2022 Aug 29
Publications & Presentations
PubMed
- 53 citations18F-FCWAY and 18F-FDG PET in MRI-negative temporal lobe epilepsyClarissa J. Liew, Young-Min Lim, Robert Bonwetsch, Sadat Shamim, Susumu Sato
Epilepsia. 2009-02-01 - 17 citationsTowards a non-invasive interictal application of hypothermia for treating seizures: a feasibility and pilot study.Anto Bagic, William H. Theodore, E. A. Boudreau, Robert Bonwetsch, Jeffrey P. Greenfield
Acta Neurologica Scandinavica. 2008-10-01 - 103 citations5-HT1A receptor binding in temporal lobe epilepsy patients with and without major depression.Gregor Hasler, Robert Bonwetsch, Giampiero Giovacchini, Maria T. Toczek, Anto Bagic
Biological Psychiatry. 2007-12-01
Press Mentions
Nuvance Participates in Trial of Drug That Could Slow Parkinson's DiseaseJuly 22nd, 2021
Professional Memberships
- Member
- Member
Other Languages
- German
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
